Some studies also highlight the potential for GLP-1 RAs to reduce upper airway fat deposition and systemic inflammation, thereby directly targeting key contributors to OSA beyond weight loss alone (108, 111). This evidence concerns the gene GLP1R and obstructive sleep apnea syndrome.